Sanofi Current Ratio 2011-2025 | SNY
Current and historical current ratio for Sanofi (SNY) from 2011 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Sanofi current ratio for the three months ending September 30, 2025 was 1.06.
| Sanofi Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-09-30 | $39.79B | $37.53B | 1.06 |
| 2025-06-30 | $42.02B | $32.99B | 1.27 |
| 2025-03-31 | $46.37B | $33.95B | 1.37 |
| 2024-12-31 | $46.08B | $31.56B | 1.46 |
| 2024-09-30 | $0.00B | 0.00 | |
| 2024-06-30 | $32.39B | $32.34B | 1.00 |
| 2024-03-31 | $0.00B | 0.00 | |
| 2023-12-31 | $33.19B | $26.19B | 1.27 |
| 2023-09-30 | $0.00B | 0.00 | |
| 2023-06-30 | $32.69B | $27.00B | 1.21 |
| 2023-03-31 | $0.00B | 0.00 | |
| 2022-12-31 | $35.85B | $25.25B | 1.42 |
| 2022-09-30 | $0.00B | 0.00 | |
| 2022-06-30 | $30.18B | $23.48B | 1.29 |
| 2022-03-31 | $0.00B | 0.00 | |
| 2021-09-30 | $0.00B | 0.00 | |
| 2021-06-30 | $35.55B | $23.05B | 1.54 |
| 2021-03-31 | $0.00B | 0.00 | |
| 2020-09-30 | $0.00B | 0.00 | |
| 2020-03-31 | $0.00B | 0.00 | |
| 2019-09-30 | $0.00B | 0.00 | |
| 2019-03-31 | $0.00B | 0.00 | |
| 2018-03-31 | $0.00B | 0.00 | |
| 2017-12-31 | $29.79B | $17.47B | 1.71 |
| 2017-09-30 | $0.00B | 0.00 | |
| 2017-06-30 | $29.78B | $18.76B | 1.59 |
| 2017-03-31 | $0.00B | 0.00 | |
| 2016-12-31 | $29.53B | $18.19B | 1.62 |
| 2016-09-30 | $0.00B | 0.00 | |
| 2016-06-30 | $25.23B | $17.22B | 1.47 |
| 2016-03-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | 0.00 | |
| 2015-06-30 | $24.35B | $18.03B | 1.35 |
| 2014-06-30 | $27.94B | $19.48B | 1.43 |
| 2013-06-30 | $27.17B | $17.80B | 1.53 |
| 2012-06-30 | $27.56B | $20.66B | 1.33 |
| 2012-03-31 | $0.00B | 0.00 | |
| 2011-12-31 | $29.05B | $18.92B | 1.54 |
| 2011-09-30 | $0.00B | 0.00 | |
| 2011-06-30 | $32.57B | $23.10B | 1.41 |
| 2011-03-31 | $0.00B | 0.00 | |
| 2010-12-31 | $35.96B | $15.62B | 2.30 |
| 2010-09-30 | $0.00B | 0.00 | |
| 2010-06-30 | $31.89B | $15.40B | 2.07 |
| 2010-03-31 | $0.00B | 0.00 | |
| 2009-12-31 | $33.30B | $17.29B | 1.93 |
| 2009-09-30 | $0.00B | 0.00 | |
| 2009-06-30 | $25.23B | $14.69B | 1.72 |
| 2009-03-31 | $0.00B | 0.00 | |
| 2008-12-31 | $22.66B | $13.75B | 1.65 |
| 2008-09-30 | $0.00B | 0.00 | |
| 2008-06-30 | $18.62B | $14.01B | 1.33 |
| 2008-03-31 | $0.00B | 0.00 | |
| 2007-12-31 | $17.21B | $13.25B | 1.30 |
| 2007-09-30 | $0.00B | 0.00 | |
| 2007-06-30 | $16.75B | $13.18B | 1.27 |
| 2007-03-31 | $0.00B | 0.00 | |
| 2006-12-31 | $15.28B | $12.91B | 1.18 |
| 2006-09-30 | $0.00B | 0.00 | |
| 2006-06-30 | $15.45B | $17.89B | 0.86 |
| 2006-03-31 | $0.00B | 0.00 | |
| 2005-12-31 | $16.34B | $19.20B | 0.85 |
| 2005-09-30 | $0.00B | 0.00 | |
| 2005-06-30 | $16.55B | $20.53B | 0.81 |
| 2005-03-31 | $0.00B | 0.00 | |
| 2004-12-31 | $15.58B | $18.67B | 0.84 |
| 2004-06-30 | $8.52B | $3.44B | 2.48 |
| 2003-12-31 | $8.86B | $3.27B | 2.72 |
| 2003-06-30 | $6.31B | $2.72B | 2.32 |
| 2002-12-31 | $6.37B | $2.67B | 2.39 |
| 2002-06-30 | $5.58B | $2.42B | 2.30 |
| 2001-12-31 | $6.38B | $2.66B | 2.40 |
| 2001-06-30 | $5.02B | $1.91B | 2.63 |
| 2000-12-31 | $5.05B | $2.11B | 2.39 |
| 1999-12-31 | $4.65B | $2.23B | 2.09 |
| 1998-12-31 | $4.26B | $2.29B | 1.86 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $121.941B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $873.885B | 42.04 |
| Johnson & Johnson (JNJ) | United States | $449.502B | 17.97 |
| AbbVie (ABBV) | United States | $387.340B | 23.19 |
| Roche Holding AG (RHHBY) | Switzerland | $267.000B | 0.00 |
| Novartis AG (NVS) | Switzerland | $266.905B | 14.15 |
| Merck (MRK) | United States | $214.149B | 9.97 |
| Novo Nordisk (NVO) | Denmark | $203.961B | 11.96 |
| Pfizer (PFE) | United States | $138.902B | 7.63 |
| Bayer (BAYRY) | Germany | $29.748B | 5.61 |
| Innoviva (INVA) | United States | $1.315B | 7.81 |